Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 5Completed 4Not yet recruiting 3Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Melanoma 41Carcinoma, Non-Small-Cell Lung 35Carcinoma, Renal Cell 26Neoplasm Metastasis 19Lung Neoplasms 18Carcinoma, Hepatocellular 15Squamous Cell Carcinoma of Head and Neck 11Colorectal Neoplasms 11Pancreatic Neoplasms 10Neoplasms 9Carcinoma, Transitional Cell 9Multiple Myeloma 8Urinary Bladder Neoplasms 7Small Cell Lung Carcinoma 7Head and Neck Neoplasms 7Breast Neoplasms 7Triple Negative Breast Neoplasms 6Ovarian Neoplasms 6Hodgkin Disease 6Advanced Cancer 6Myelodysplastic Syndromes 5Hematologic Neoplasms 5Brain Neoplasms 5Skin Neoplasms 4Recurrence 4Lymphoma 4Kidney Neoplasms 4Glioblastoma 4Fallopian Tube Neoplasms 4Uveal Melanoma 3

Interventions

pembrolizumab 2Sunitinib 2sitravatinib 1pazopanib 1atezolizumab 1aldesleukin 1Nivolumab 1Nephrectomy 1Metastasectomy 1LY2510924 1Immunoglobulin G 1Cytoreduction Surgical Procedures 1Axitinib 1Ascorbic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Clear-cell metastatic renal cell carcinoma × Nivolumab × Clear all
NCT04904302 2026-03-20

Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer

M.D. Anderson Cancer Center

Phase 2 Terminated
15 enrolled
Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡